ClinicalTrials.gg
CompletedNCT02119234TRIPLE 4Updated Oct 29, 2021

Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients

A Phase 1 interventional study of Beclometasone/formoterol/glycopyrrolate and Placebo in COPD, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Poland. Open to participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
45 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. Beclomethasone · Pulmonary Disease, Chronic Obstructive.

Enrollment
4th of 13
36 · median 24
Started
2014
with 2 others
Phase 1
3 of 13
none open now
Registered
8th of 13
by date
Lead sponsor
6 of 13
Chiesi Farmaceutici S.p.A.

Among the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive, this one is the 4th largest by enrollment, is one of 3 that started in 2014, is one of 3 in phase 1, and was the 8th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 45 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The study is performed to investigate the effect of the spacing device on the pharmacokinetics of CHF 5993 pMDI active ingredients administered with and without Aerochamber Plus Flow-vu antistatic VHC spacer as a single administration in COPD patients. Moreover, the general safety and tolerability of the treatments will be evaluated.

03

Conditions studied

04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients
  • smokers or ex-smokers
  • post-bronchodilator between 30 and 60% of predicted value

Exclusion criteria

Exclusion Criteria:

  • Positive serology to and hepatitis
  • Known respiratory disorder other than
  • Recent COPD exacerbations or hospitalization for COPD
  • Treatment with non-permitted concomitant medication
  • concomitant disease
  • clinically relevant abnormal laboratory or parameters
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    CHF5993 pMDI + Spacer

    CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using Aerochamber Plus Flow-vu VHC spacer

    Drug: Beclometasone/formoterol/glycopyrrolate

  • Active comparator
    CHF5993 pMDI

    CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using standard actuator only

    Drug: Beclometasone/formoterol/glycopyrrolate

  • Placebo comparator
    Placebo pMDI

    Placebo pMDI x 4 inhalations

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the curve of B17MP, formoterol and glycopyrrolate

    AUCt (up to the last quantifiable concentration) and Cmax (maximum concentration) from plasma concentrations vs time profiles. over 24h for formoterol and B17MP, over 48h for glycopyrrolate

    Time frame: Over 24 and 48h after single administration

Secondary outcomes

  1. Other pharmacokinetic parameters for formoterol, glycopyrrolate and B17MP in plasma

    B17MP AUC0-30min, AUC0-24h, AUCinf, tmax, half-life Formoterol AUC0-30min, AUC0-24h, AUCinf, tmax, half-life Glycopyrrolate AUC0-30min, AUC0-48h, AUCinf, tmax, half-life

    Time frame: over 24 or 48h after single administration

  2. Adverse events

    from the signature of the informed consent until the follow-up phone call

    Time frame: over a period of 6 to 11 weeks

  3. Lung function

    FEV1

    Time frame: 30 min after single administration

  4. plasma cortisol

    cortisol AUC0-24h, Cmin and tmin

    Time frame: over 24 h after single administration

  5. cortisol urinary excretion

    cortisol excretion corrected and not corrected for creatinine

    Time frame: over 24 h after single administration

  6. potassium plasma profile

    potassium AUC0-24h, tmin and Cmin

    Time frame: over 24 h after single administration

  7. Vital signs

    systolic and diastolic blood pressure

    Time frame: over 24 h after single administration

  8. ECG parameters

    extracted from holter recording HR, QTcF, PR and QRS

    Time frame: over 24 h after single administration

07

Study locations

1 site
  • Medical University in Lodz
    Lodz, Ul. Kopcińskiego 22 90-153, Poland
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2014
First posted
Apr 21, 2014
Start
Mar 2014
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Oct 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02119234
Responsible party
Sponsor
First posted
Apr 21, 2014
Start date
Mar 2014
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Oct 29, 2021

Study contacts

Piotr Kuna, MD
principal investigator · Medical University Lodz

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Beclomethasone · Formoterol · Glycopyrrolate

Start the discussion